Skip to content

Comparison of two different drugs for spinal anaesthesia in parturients undergoing caesarean sections

Comparision of Intrathecal Magnesium sulphate as adjuvant to 0.5% hyperbaric Bupivacaine & 0.5% isobaric Levobupivacaine in parturients undergoing elective cesarean sections.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/12/016660
Enrollment
60
Registered
2018-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Isobaric levobupivacaine with magnesium sulphate: Isobaric levobupivacaine with 75 mg of magnesium sulphate injected intrathecally Intervention2: Hyperbaric bupivacaine with magnesium s

Sponsors

Sapthagiri institute of medical sciences and research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: parturients with gestational age of 37 to 42 weeks having singleton pregnancy with average height of 150 to 170 cms, coming for elective caesarian section

Exclusion criteria

Exclusion criteria: Parturients with contraindications to spinal anaesthesia, known allergy to local anaesthetics, other medical illnesses like diabetes, pregnancy induced hypertension, hypothyroidism, severe anaemia( <7gm/dl)

Design outcomes

Primary

MeasureTime frame
Effects on duration of postoperative analgesia based on visual analogue scale and onset and duration of motor and sensory anaesthesia based on Bromage grading and blunt tip pin prick sensationTimepoint: 12 hours postoperatively

Secondary

MeasureTime frame
Effects on haemodynamic stability and any side effectsTimepoint: 12 hours postoperatively

Countries

India

Contacts

Public ContactDeepa Chandran

Sapthagiri institute of medical sciences and research centre

deepachandran@rediffmail.com9945063487

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026